Company · updated daily

Adamas Pharmaceuticals was named in a securities class action settlement covering investors who purchased or acquired its publicly traded common stock between August 8, 2017 and March 4, 2019. The $4,650,000 total settlement fund provided an estimated average recovery of approximately $0.27 per eligible share for those who suffered losses during the class period. Note that the official claim deadline of August 28, 2024 has passed. This settlement record is maintained for reference.